Cargando…

Analysis of the clinical characteristics of pembrolizumab-induced bullous pemphigoid

BACKGROUND: Pembrolizumab, a programmed cell death protein 1 checkpoint inhibitor, is a novel drug used to treat a variety of advanced malignancies. However, it can also result in many immune-related adverse events, with cutaneous toxicities being the most frequent. Regarding pembrolizumab-induced s...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Jianglin, Hu, Xin, Jiang, Wei, Zhou, Wenjie, Tang, Mengjie, Wu, Cuifang, Liu, Wei, Zuo, Xiaocong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10022695/
https://www.ncbi.nlm.nih.gov/pubmed/36937423
http://dx.doi.org/10.3389/fonc.2023.1095694
_version_ 1784908775109427200
author Wang, Jianglin
Hu, Xin
Jiang, Wei
Zhou, Wenjie
Tang, Mengjie
Wu, Cuifang
Liu, Wei
Zuo, Xiaocong
author_facet Wang, Jianglin
Hu, Xin
Jiang, Wei
Zhou, Wenjie
Tang, Mengjie
Wu, Cuifang
Liu, Wei
Zuo, Xiaocong
author_sort Wang, Jianglin
collection PubMed
description BACKGROUND: Pembrolizumab, a programmed cell death protein 1 checkpoint inhibitor, is a novel drug used to treat a variety of advanced malignancies. However, it can also result in many immune-related adverse events, with cutaneous toxicities being the most frequent. Regarding pembrolizumab-induced skin adverse reactions, bullous pemphigoid (BP) has the worst effects on quality of life. Recently, there have been more and more reports of BP incidents resulting from pembrolizumab therapy in patients with cancer. This study aimed to define the clinical characteristics, diagnosis and management of pembrolizumab-induced BP and identify potential differences between classical BP and pembrolizumab-induced BP. METHODS: Case reports, case series, and case analyses of pembrolizumab-induced BP up to 10 December 2022 were collected for retrospective analysis. RESULTS: Our study included 47 patients (33 males and 14 females) from 40 studies. The median age was 72 years (range 42-86 years). The median time to cutaneous toxicity was 4 months (range 0.7-28 months), and the median time to bullae formation was 7.35 months (range 0.7-32 months). The most common clinical features were tense bullae and blisters (85.11%), pruritus (72.34%), and erythema (63.83%) on the limbs and trunk. In 20 of the 22 cases tested, the serum anti-BP180 autoantibodies were positive. However, in 10 cases (91.90%, 10/11) the circulating autoantibodies of anti-BP230 were negative. 40 patients had skin biopsies and the skin biopsy revealed subepidermal bullae or blister eosinophil infiltration in 75.00% of patients with pembrolizumab-induced BP, 10.00% of patients with lymphocyte infiltration and 20.00% of patients with neutrophil infiltration. There were 20 patients (50%) with eosinophilic infiltration around the superficial dermis vessels, 8 patients (20.00%) with lymphocyte infiltration around the superficial dermis vessels, and 4 patients (10.00%) with neutrophil infiltration around the superficial dermis vessels. Direct immunofluorescence detected linear immunoglobulin G (IgG) IgG and/or complement C3 along the dermo-epidermal junction in 36 patients (94.74%) with BP. IgG positivity was detected by indirect immunofluorescence in 81.82% of patients with BP. All patients were in complete remission (95.65%,44/46) or partial remission (4.35%, 2/46) of BP, whereas 9/46 patients had a relapse or refractory. The majority of patients achieved BP remission after discontinuation of pembrolizumab with a combination of topically and systemically administered steroid treatments, or other medications. The median duration of BP remission was 2 months (range 0.3-15 months). CONCLUSION: A thorough diagnosis of pembrolizumab-induced BP should be made using clinical signs, biochemical markers, histopathological and immunopathological tests. Pembrolizumab-induced BP had similar clinical characteristics to classic BP. Temporary or permanent discontinuation of pembrolizumab therapy may be required in patients with perbolizumab-induced BP depending on the severity of BP and the response to medication. Pembrolizumab-induced BP may be effectively treated using topical and systemic steroid treatments in combination with other medications (e.g., doxycycline, niacinamide, dapsone, rituximab, intravenous immunoglobulins, dupilumab, cyclophosphamide, methotrexate, mycophenolate mofetil, and infliximab). Clinicians should provide better management to patients with BP receiving pembrolizumab to prevent progression and ensure continuous cancer treatment.
format Online
Article
Text
id pubmed-10022695
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-100226952023-03-18 Analysis of the clinical characteristics of pembrolizumab-induced bullous pemphigoid Wang, Jianglin Hu, Xin Jiang, Wei Zhou, Wenjie Tang, Mengjie Wu, Cuifang Liu, Wei Zuo, Xiaocong Front Oncol Oncology BACKGROUND: Pembrolizumab, a programmed cell death protein 1 checkpoint inhibitor, is a novel drug used to treat a variety of advanced malignancies. However, it can also result in many immune-related adverse events, with cutaneous toxicities being the most frequent. Regarding pembrolizumab-induced skin adverse reactions, bullous pemphigoid (BP) has the worst effects on quality of life. Recently, there have been more and more reports of BP incidents resulting from pembrolizumab therapy in patients with cancer. This study aimed to define the clinical characteristics, diagnosis and management of pembrolizumab-induced BP and identify potential differences between classical BP and pembrolizumab-induced BP. METHODS: Case reports, case series, and case analyses of pembrolizumab-induced BP up to 10 December 2022 were collected for retrospective analysis. RESULTS: Our study included 47 patients (33 males and 14 females) from 40 studies. The median age was 72 years (range 42-86 years). The median time to cutaneous toxicity was 4 months (range 0.7-28 months), and the median time to bullae formation was 7.35 months (range 0.7-32 months). The most common clinical features were tense bullae and blisters (85.11%), pruritus (72.34%), and erythema (63.83%) on the limbs and trunk. In 20 of the 22 cases tested, the serum anti-BP180 autoantibodies were positive. However, in 10 cases (91.90%, 10/11) the circulating autoantibodies of anti-BP230 were negative. 40 patients had skin biopsies and the skin biopsy revealed subepidermal bullae or blister eosinophil infiltration in 75.00% of patients with pembrolizumab-induced BP, 10.00% of patients with lymphocyte infiltration and 20.00% of patients with neutrophil infiltration. There were 20 patients (50%) with eosinophilic infiltration around the superficial dermis vessels, 8 patients (20.00%) with lymphocyte infiltration around the superficial dermis vessels, and 4 patients (10.00%) with neutrophil infiltration around the superficial dermis vessels. Direct immunofluorescence detected linear immunoglobulin G (IgG) IgG and/or complement C3 along the dermo-epidermal junction in 36 patients (94.74%) with BP. IgG positivity was detected by indirect immunofluorescence in 81.82% of patients with BP. All patients were in complete remission (95.65%,44/46) or partial remission (4.35%, 2/46) of BP, whereas 9/46 patients had a relapse or refractory. The majority of patients achieved BP remission after discontinuation of pembrolizumab with a combination of topically and systemically administered steroid treatments, or other medications. The median duration of BP remission was 2 months (range 0.3-15 months). CONCLUSION: A thorough diagnosis of pembrolizumab-induced BP should be made using clinical signs, biochemical markers, histopathological and immunopathological tests. Pembrolizumab-induced BP had similar clinical characteristics to classic BP. Temporary or permanent discontinuation of pembrolizumab therapy may be required in patients with perbolizumab-induced BP depending on the severity of BP and the response to medication. Pembrolizumab-induced BP may be effectively treated using topical and systemic steroid treatments in combination with other medications (e.g., doxycycline, niacinamide, dapsone, rituximab, intravenous immunoglobulins, dupilumab, cyclophosphamide, methotrexate, mycophenolate mofetil, and infliximab). Clinicians should provide better management to patients with BP receiving pembrolizumab to prevent progression and ensure continuous cancer treatment. Frontiers Media S.A. 2023-03-03 /pmc/articles/PMC10022695/ /pubmed/36937423 http://dx.doi.org/10.3389/fonc.2023.1095694 Text en Copyright © 2023 Wang, Hu, Jiang, Zhou, Tang, Wu, Liu and Zuo https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Wang, Jianglin
Hu, Xin
Jiang, Wei
Zhou, Wenjie
Tang, Mengjie
Wu, Cuifang
Liu, Wei
Zuo, Xiaocong
Analysis of the clinical characteristics of pembrolizumab-induced bullous pemphigoid
title Analysis of the clinical characteristics of pembrolizumab-induced bullous pemphigoid
title_full Analysis of the clinical characteristics of pembrolizumab-induced bullous pemphigoid
title_fullStr Analysis of the clinical characteristics of pembrolizumab-induced bullous pemphigoid
title_full_unstemmed Analysis of the clinical characteristics of pembrolizumab-induced bullous pemphigoid
title_short Analysis of the clinical characteristics of pembrolizumab-induced bullous pemphigoid
title_sort analysis of the clinical characteristics of pembrolizumab-induced bullous pemphigoid
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10022695/
https://www.ncbi.nlm.nih.gov/pubmed/36937423
http://dx.doi.org/10.3389/fonc.2023.1095694
work_keys_str_mv AT wangjianglin analysisoftheclinicalcharacteristicsofpembrolizumabinducedbullouspemphigoid
AT huxin analysisoftheclinicalcharacteristicsofpembrolizumabinducedbullouspemphigoid
AT jiangwei analysisoftheclinicalcharacteristicsofpembrolizumabinducedbullouspemphigoid
AT zhouwenjie analysisoftheclinicalcharacteristicsofpembrolizumabinducedbullouspemphigoid
AT tangmengjie analysisoftheclinicalcharacteristicsofpembrolizumabinducedbullouspemphigoid
AT wucuifang analysisoftheclinicalcharacteristicsofpembrolizumabinducedbullouspemphigoid
AT liuwei analysisoftheclinicalcharacteristicsofpembrolizumabinducedbullouspemphigoid
AT zuoxiaocong analysisoftheclinicalcharacteristicsofpembrolizumabinducedbullouspemphigoid